The TrumpRx cash-pay drug purchasing portal has officially launched, marking the rollout of a government-run website that directs patients to cash-pay channels for purchasing prescription drugs without insurance.
President Donald Trump debuted TrumpRx.gov on Thursday evening after a brief delay, positioning the platform as part of the administration’s broader healthcare and drug pricing agenda. The website initially features 40 branded medicines from five pharmaceutical companies that have reached drug pricing agreements with the White House: AstraZeneca, Eli Lilly, Merck KGaA’s EMD Serono, Novo Nordisk, and Pfizer.
Among the drugs listed on the TrumpRx cash-pay drug purchasing portal are Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy, including the newly launched Wegovy pill, fertility medications from EMD Serono, multiple AstraZeneca inhalers, and Pfizer’s eczema treatment Eucrisa.
Trump first previewed the direct-to-patient purchasing tool in September alongside the announcement of so-called most-favored-nation drug pricing deals. Pfizer, the first major company to sign such an agreement, launched its TrumpRx offering with 30 medicines available at self-pay discounts of up to 85%, according to a company press release.
TrumpRx doesn’t sell drugs itself. Prices listed on the site are cash prices powered by GoodRx technology. Then TrumpRx sends customers elsewhere to buy. Many pharmacies pushing back against TrumpRx are the companies’ own websites. Coupons are printed by patients in some cases.
“We’re continuing to make it easier for people to access our authentic, FDA approved medicines by expanding availability through multiple, convenient options,” Novo’s associate VP of U.S. public affairs, Chris Pernie, said in an emailed statement to Fierce.
GoodRx confirmed it is a “core integration partner” for TrumpRx in a press release issued alongside the site’s launch. Last year, Trump urged 17 drugmakers to pursue direct-to-patient sales as part of a broader effort to align U.S. drug prices with those in other developed countries.
Analysts have had mixed reactions towards the portal. University of Washington health economists projected that TrumpRx will do little to help most Americans who already have prescription drug coverage. Patients for Affordable Drugs Now, an advocacy group, expressed concerns over voluntary pricing commitments and lack of repercussions.
Lawmakers have also questioned whether TrumpRx complies with federal anti-kickback laws, citing unresolved oversight and transparency issues surrounding the platform’s structure and legal authority.